Coronavirus Information and Resources
Siletz Community Health Clinic
•
•
•
COVID-19 – Vaccine Information
Purchased/Referred Care – Newly Available Service
16- and 17-year-olds able to receive COVID-19 vaccine
at Pfizer COVID-19 vaccine clinic
PRC funding for specialty surgery
In Siletz on April 16, 2021, by appointment
Available to Tribal members and household members ages 16-17
To schedule an appointment:
∗ Text 541-270-5603 with your:
First and last name and date of birth
Texting option is only for scheduling 16- and 17-year-olds (at this time)
∗ Or call
541-444-9636 (specify age and Pfizer vaccine)
Tribal Council has approved funding for medically necessary surgeries that are not
currently approved services. To qualify, you must be an enrolled Siletz Tribal member
AND PRC-eligible. Eligible surgeries:
• Excess eyelid skin removal
• Breast reduction
• Excess abdominal skin removal
PRC will process requests through Gatekeepers; funding is limited and will be
first-come, first-served. The established medically necessary criteria are consistent
with CMS and insurance guidelines. Requests deemed as cosmetic will not qualify.
Covid-19 vaccines available for all – age 18 and older – Tribal members,
Tribal households/family members/friends, patients, community members
Moderna COVID-19 Vaccine Clinic(s)
•
In Siletz every Friday by appointment (Tribal members and family are priority)
∗ To schedule, call: 541-444-9636
Johnson & Johnson vaccine – 1 shot only
The clinic is requesting a supply of the Johnson & Johnson vaccine – 1 shot only.
Please watch the Tribal website and the clinic’s Facebook page for the latest updates.
We hope it will be available soon but do not have a date yet.
Traveling to Siletz for vaccine
Resources available to enrolled Tribal members
•
•
The following resources are available:
Lodging for out-of-state OR southern/central/eastern Oregon travelers – at time of
scheduling your vaccine, let the scheduler know you’re traveling a long distance.
Gas cards – limited supply available at COVID clinics
Be safe. Stay home. Stay well.
Vaccine
developer:
Pfizer
Moderna
Johnson & Johnson
AstraZeneca
Novavax
Prepared by the Northwest Portland Area Indian Health Board (NPAIHB)
Updated 3/1/2021
Who can
receive this
vaccine?
16 years and older
18 years and older
18 years and older
18 years and older
18 years and
older
Pfizer
Moderna
Johnson &
Johnson
AstraZeneca
Novavax
How it works
Messenger RNA
Messenger RNA
Inactivated Adeno-
virus base (Non-
replicating vector
vaccine)
Inactivated
Adeno-virus base
(Non-replicating
vector vaccine)
Protein-based
(recombinant
nanoparticle tech)
December 11,
2020
December 18,
2020
February 27, 2021
Has not
submitted
application for
EUA in U.S. yet,
but possibly in
April
Has not
submitted
application for
EUA in U.S. yet.
Currently in phase
3 clinical trials
The vaccine has not
yet been studied in
pregnant or lactating
women. Pregnant
women are allowed
to get the vaccine,
but should first
consult with their
doctor. mRNA
vaccines are not
thought to be a risk
to the breastfeeding
infant
The vaccine has not
yet been studied in
pregnant or lactating
women. Pregnant
women are allowed
to get the vaccine,
but should first
consult with their
doctor.
Date approved/
Expected
approval
The vaccine has not
yet been studied in
pregnant or lactating
women. Pregnant
women are allowed
to get the vaccine,
but should first
consult with their
doctor. mRNA
vaccines are not
thought to be a risk
to the breastfeeding
infant
The vaccine has not
yet been studied in
pregnant or
lactating women.
Pregnant women
are allowed to get
the vaccine, but
should first consult
with their doctor.
The vaccine is not
considered to be a
risk to the
breastfeeding infant
Not yet
available
Vaccine
developer:
What about
pregnant and
breastfeeding
women?
Who should
not get this
vaccine?
Caution and
consultation should
be taken with
persons who have a
history of serious
allergic reactions.
Contraindicated in
people with prior
reactions to vaccine
ingredients
Caution and
consultation should
be taken with
persons who have a
history of serious
allergic reactions.
Contraindicated in
people with prior
reactions to vaccine
ingredients
Contraindicated in
people with prior
reactions to vaccine
ingredients
The vaccine should
not be given to
those who have had
a previous severe
allergic reaction to a
previous dose of the
same COVID-19
vaccine or an
ingredient in the
COVID-19 vaccine
Not yet
available
Any significant
side effects?
During December
14–23, 2020, there
were 21 cases of
anaphylaxis after the
first dose. 4 cases of
Bell’s palsy in clinical
trial vaccine group
During December 21,
2020–January 10,
2021, there were 10
cases of anaphylaxis
after the first dose. 3
cases of Bell’s palsy
in clinical trial
vaccine group
One case of hives and
swelling of the lips,
one case of severe
pain in the injected
arm, and one case of
generalized
weakness, fever, and
headache
Four total serious
adverse events,
including one case
of transverse
myelitis
Not yet
available
What about
people with
lowered
immune
function and
autoimmune
diseases?
Ok for people whose
immune function is
lowered by HIV,
immunosuppressing
drugs, or
autoimmune disease.
People with these
conditions may still
get the vaccine if
they have no other
contraindications.
There is limited
safety data in this
group
Ok for people whose
immune function is
lowered by HIV,
immunosuppressing
drugs, or
autoimmune disease.
People with these
conditions may still
get the vaccine if
they have no other
contraindications.
There is limited
safety data in this
group
Ok for people whose
immune function is
lowered by HIV,
immunosuppressing
drugs, or
autoimmune disease.
People with these
conditions may still
get the vaccine if
they have no other
contraindications.
There is limited
safety data in this
group
Not yet available
Not yet
available
COVID-19 Vaccine Review
Efficacy in
preventing
COVID-19 related
hospitalization
and death
All five vaccines (Pfizer, Moderna, Johnson & Johnson, AstraZeneca and Novavax)
have demonstrated efficacy in preventing severe COVID-19 disease,
hospitalizations and deaths. Out of 75,000 people who have received these
vaccines as part of research studies, no one, has died from COVID-19.
What percentage
of people did it
protect from
getting infected
in clinical
studies?
95% efficacy to
prevent
symptomatic
COVID-19 infection
after 2 doses
94.1% efficacy to
prevent
symptomatic
COVID-19
infection after 2
doses; 86.4% for
those ≥65
66-72% efficacy to
prevent
symptomatic
COVID-19 infection
after 1 dose;
85% efficacy in
preventing severe
disease
70.4% efficacy to
prevent
symptomatic
COVID-19 infection
after 2 doses
89.3% efficacy
to prevent
symptomatic
COVID-19
infection after 2
doses in UK,
85.6% for B.117
strain
How many shots
do you need?
Two doses, 3
weeks (or 21 days)
apart
Two doses, 4
weeks (or 28 days)
apart
One dose
Two doses, 4 weeks
(or 28 days) apart
Two doses, 3
weeks (or 21
days) apart
What are the
potential side
effects?
Fatigue, headache,
chills, muscle
aches, especially
after the second
dose
Fever, muscle
aches, headaches
lasting a few days.
Effects worse after
second dose
Fatigue, headache,
muscle aches,
nausea and
injection site pain
Injection site pain,
fever, muscle aches,
headache
Fatigue,
headache,
muscle aches
and injection
site pain
Storage
-112°F to -76°F
(before mixing,
vaccine may be
stored at 36°F to
46°F for up to 120
hours or 5 days)
-13°F to 5°F
(vaccine vials may
be stored at 36°F
to 40°F for 1
month or 30 days)
36° to 46°F (may be
stored at 36° to
46°F for at least 3
months)
36°F to 46°F (may
be stored at 36°F to
46°F for at least 6
months)
36°F to 46°F
(ready to use)
Summary is continued on the other side
10 •
Siletz News
•
April 2021
For more information please visit https://www.cdc.gov/coronavirus/2019-ncov/vaccines/
Updated 3/1/2021